It is important to appreciate that there are key pathological differences between STEMI and ischemic stroke. STEMI is usually the result of plaque rupture and in-situ thrombosis, whereas ischemic stroke most often results from athero-thrombotic embolism. (6) The outcome of large strokes is very poor. The reported mortality for untreated terminal occlusion of the internal carotid artery (ICA) is 53% and up to 90% for basilar artery occlusion. The vast majority of those who survive are left with severe neurological disability.
STROKE : INITIAL EVALUATION
Initial evaluation involves assessing the clinical defi cit according to the National Institute of Health Stroke Scale (NIHSS) (www.ninds.nih.gov/ doctors/NIH_Stroke_Scale.pdf). This score (0-42 with 0 being normal) is used to assess stroke severity and to help guide management decisions. Strokes can be divided into mild (NIHSS score <7), moderate (8) (9) (10) (11) (12) (13) (14) (15) (16) , severe (17-24) and very severe (>24). Urgent brain imaging, either by CT scanning or MRI is mandatory. The primary purpose of the initial scan is to rule out a hemorrhagic stroke, which is managed differently. More sophisticated MR perfusion-diffusion or CT perfusion scans can be obtained to assess the size of the ischemic but still viable brain tissue surrounding the infarcted area (ischemic penumbra). This may help to predict the response to reperfusion therapy. However, these scans are more expensive and, more importantly, time consuming.
Current data suggests that the majority of strokes will have a signifi cant ischemic penumbra within the fi rst 6 to 8 hours of stroke onset and may well benefi t from reperfusion therapy. (7, 15) 
INTRAVENOUS THROMBOLYSIS
Intravenous tissue Plasminogen Activator (tPA) (0.9mg/kg, maximum dose 90mg) carries the strongest recommendation for patients who present within 3 hours of ischemic stroke onset (Class I; Level of Evidence A). (7) In the United States, however, only 2% of all ischemic stroke patients actually get this therapy, (6) mainly because patients present beyond the 3-hour cut off. In the landmark NINDS Trial (2) comparing iv tPA to placebo in patients presenting within 3 hours of onset (median NIHSS score 14), 21% of the placebo group vs. 34% of reperfusion should be the primary therapeutic strategy for ischemic stroke. However, the therapeutic window for intravenous (iv) thrombolysis is very narrow, being less than 3 hours after stroke onset. (2) This window can be extended for up to 6 hours for intra-arterial (ia) thrombolysis. (3, 4) and for up to 8 hours for mechanical embolectomy.
PERCUTANEOUS INTERVENTION IN ACUTE STROKE
the tPA group achieved full recovery at 3 months (P<0.05). However, there was no overall mortality difference. The intracerebral bleeding rate was 6.4% with tPA and 0.6% in placebo treated patients.
Intravenous tPA has limited effi cacy. In a study using transcranial Doppler 1 hour following iv tPA given within 3 hours of stroke onset, complete vessel patency is obtained in only 17% of cases, with partial fl ow in 28% and no recanalization in over half the cases. (9) The effi cacy of iv tPA also depends on the site of arterial occlusion. Patency rates following iv tPA for terminal internal carotid artery (ICA) occlusion is less than 10%. It is approximately 30% for basilar and proximal middle cerebral artery (MCA) occlusions and 50% for mid MCA occlusions. (10) One-year outcome data from the NINDS trial (14) showed no benefi t of iv tPA in those patients with a baseline very large stroke (NIHSS score >20).
CATHETER-BASED THERAPY

Intra-arterial Thrombolysis
The intra-arterial approach has been promoted because a high concentration of thrombolytic agent may be delivered into the thrombus. Despite the uncontrolled observation that recanalization rates may be higher with ia thrombolysis than with iv thrombolysis, clinical benefi t may be counterbalanced by delays to initiating treatment with the ia approach.
Intra-arterial administration of at least one specifi c thrombolytic agent, recombinant prourokinase, appears to be of some benefi t in treatment of carefully selected patients with acute ischemic stroke secondary to occlusion of the MCA. No difference in overall death rate was seen between the 2 groups.
The FDA has not approved the drug, and recombinant prourokinase is not currently available for clinical use. Extrapolation to tPA, the widely used iv cerebral thrombolytic drug, and to urokinase, which is chemically similar to the prourokinase prodrug, is based on consensus and case series data. Intra-arterial tPA has also been studied in combination with lower dose iv therapy (0.6mg/kg) with promising results warranting further study.
Mechanical Embolectomy
Mechanical embolectomy using the FDA approved Merci Retriever (Concentric Medical Mountain View, California, USA) is a new device used to extract the offending thrombo-embolus from large intracerebral vessels up to 8 hours post stroke onset. (5) It may also be used safely in a combination with either iv or ia tPA.
The Merci (5) and Multi Merci trials (11) were prospective, nonrandomized, 
Revascularization correlated with a good clinical outcome (Modifi ed The L5 device is a helix of fl exible nitinol wire with an arcade of fi laments secured to the loops of the helix. This differs from the X5 and X6 Merci Retrievers by having fi laments and no taper to the coils. Within 8 hours of acute ischemic stroke, the balloon guide catheter is placed via femoral artery into the proximal internal carotid or vertebral artery. The blue microcatheter is advanced through the balloon guide catheter and placed through the occlusion using a microguidewire. The guidewire is then exchanged for the Retriever, which is advanced distal to the clot and several loops are deployed (A). The device is further deployed so as to fully ensnare the clot (B). Then, the proximal balloon of the guide is infl ated to prevent distal embolization, some torquing maneuvers are applied, and the microcatheter and Retriever are withdrawn together to retrieve the clot (C). successfully revascularised compared to just 9.6% where revascularization failed (p<0.001). Mortality at 90 days was 25% against 52% respectively (p<0.001) The rate of symptomatic intracerebral hemorrhage was 9.8% in the Multi Merci trial; however, only 2.4% were sizable enough to cause mass effect. (11) This compared to 6.4% with iv tPA alone in the NINDS trial. (2) With growing experience and subtle device and technique modifi cations vessel patency rates of up to 83.6% are obtainable. (12) Mechanical embolectomy is undergoing further analysis in the MR Rescue and IMS-2 trials. Both trials are randomized and will provide important effi cacy data with primary clinical outcomes.
In a recent meta-analysis on the impact of recanalization (spontaneous, post thrombolytic or mechanical) on ischemic stroke outcome, (12) clinical outcome at 3 months is strongly related to successful reperfusion (odds ratio 4.43. p<0.0001). Three month mortality was signifi cantly reduced in recanalized patients (odds ratio 0.24. p<0.0001). Rates of symptomatic hemorrhagic transformation did not differ between the two groups ( Figure 2 ).
To date, the author has used the Merci Retriever in six cases (Table 1) .
Average age of 65 years, symptom duration of 4.2 hours and NIHSS score = 32. In one case with a proximal middle cerebral artery occlusion it was not possible to deploy the device due to extensive vessel tortuosity. The patient was given ia tPA alone but failed to re-canalize and she suffered a large stroke. The device was successfully deployed in the other fi ve cases (four terminal ICA occlusions (Figure 3 ), one distal basilar artery occlusion) and vessel patency of 100% was obtained.
Intra-arterial tPA was given in all cases (total dose 5-15mg) in conjunction with the Merci Retriever. One patient died four days post procedure due to a massive stroke, while the outcome of the four successful patients far exceeded the expected prognosis for such large strokes. There were no symptomatic intracerebral hemorrhages.
BRAIN ATTACKS -IMPROVING PATIENT ACCESS TO CATHETER BASED THERAPY
Early reperfusion with catheter based therapy, that is a short door-toballoon time, is the optimal treatment for acute myocardial infarction and it will most likely become the optimal treatment for selected large vessel acute ischemic stroke patients. Without reperfusion therapy these patients have a very poor prognosis. However, very few arrive at hospital in time for possible iv thrombolysis (<10%), which when given has limited effi cacy in opening large vessel occlusions (<30%).
Mechanical embolectomy has been shown to be safe and effective up to 8 hours after stroke onset, thereby allowing far more severe acute stroke patients the option of revascularization and its proven benefi ts.
Unfortunately there is a severe shortage of neuro-interventionalists in South Africa (approximately 7)(personal communication), and indeed worldwide. In the United States, there are only 385 interventional neuro-radiologists. (13) Clearly in order to provide a 24-hour a day, 365 days per year emergency stroke service a vast increase in the number of skilled neuro-interventionalists is required. It has been proposed that the larger multi-specialty community of carotid interventionalists begin to fi ll this gap. (13) These specialists (cardiologists, vascular surgeons,
The impact of recanalization on ischemic stroke outcome: a meta analysis of 53 studies involving 2066 patients. (12) Endpoints assessed were clinical outcome, mortality and hemorrhagic transformation of the infarct. 
